Pharming Group (NASDAQ:PHAR) Stock Rating Lowered by Wall Street Zen

Pharming Group (NASDAQ:PHAR) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

PHAR has been the topic of a number of other reports. Oppenheimer reiterated an “outperform” rating and set a $41.00 target price (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Canaccord Genuity Group began coverage on Pharming Group in a research report on Friday, April 10th. They set a “buy” rating and a $37.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, March 24th. Finally, Weiss Ratings upgraded Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, April 27th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Pharming Group Price Performance

Pharming Group stock opened at $12.98 on Friday. The business has a fifty day moving average of $16.28 and a two-hundred day moving average of $16.56. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.06 and a current ratio of 2.63. The company has a market cap of $916.65 million, a P/E ratio of 81.13 and a beta of 0.04. Pharming Group has a one year low of $8.69 and a one year high of $21.34.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The firm had revenue of $72.45 million for the quarter, compared to analysts’ expectations of $92.06 million. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%. As a group, analysts predict that Pharming Group will post 0.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

Several institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC increased its stake in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the last quarter. Millennium Management LLC acquired a new position in Pharming Group in the fourth quarter valued at $360,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group in the fourth quarter valued at $224,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Pharming Group in the second quarter valued at $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.